Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 10 November 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Domestic demand for raw materials in the Fine Chemicals segment has remained firm, while sales of material solutions-related products, mainly electronic materials, have increased in the Life Sciences segment. The increase in revenue and a review of selling prices have offset the impact of lower earnings in certain businesses, and business progress to date has exceeded initial expectations.
| Item | Details |
|---|---|
| Net Sales | ¥130,000 million → ¥133,000 million（+2.3%） |
| Operating profit | ¥6,200 million → ¥6,500 million（+4.8%） |
| Ordinary income | ¥6,500 million → ¥6,600 million（+1.5%） |
| Profit attributable to owners of the parent | ¥4,100 million → ¥4,800 million（+17.0%） |
| Net income per share | 142.31 yen and sen → 83.28 yen and sen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 10 November 2025 |
| Previous-period results | Revenue: ¥132,703 million; operating profit: ¥6,430 million; ordinary profit: ¥6,879 million; net income attributable to owners of the parent: ¥4,615 million; earnings per share: ¥160.23 |
| Reason for the revision | Domestic demand for raw materials in the Fine Chemicals segment has remained firm, while sales of material solutions-related products, mainly electronic materials, have increased in the Life Sciences segment. The increase in revenue and a review of selling prices have offset the impact of lower earnings in certain businesses, and business progress to date has exceeded initial expectations. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Domestic demand for raw materials in the Fine Chemicals segment has remained firm, while sales of material solutions-related products in the Life Sciences segment have also increased. The increase in revenue and a review of selling prices have offset the impact of lower earnings in certain businesses, including the marine development-related and biotech-related businesses, and business progress to date has exceeded initial expectations.